Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ranbaxy Board Approves Separate Research Unit, Plans Share Listing This Year

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Ranbaxy Laboratories' board Feb. 19 approved setting up a research unit called Ranbaxy Life Science Research Ltd., the latest foray by Indian generic pharma firms to create dedicated research and development arms to cut expenses on the parent balance sheet and attract new contract business

You may also be interested in...



Ranbaxy To Announce New Drug Development Tie-Up In May

NEW DELHI - India's top generic drug firm Ranbaxy Laboratories expects to announce a new tie up with a large multinational drug firm in May to develop new chemical entities at its recently spun-off Life Science Research unit similar to a current deal with GlaxoSmithKline inked in 2003 and expanded last year, the company's chief executive said

Ranbaxy To Announce New Drug Development Tie-Up In May

NEW DELHI - India's top generic drug firm Ranbaxy Laboratories expects to announce a new tie up with a large multinational drug firm in May to develop new chemical entities at its recently spun-off Life Science Research unit similar to a current deal with GlaxoSmithKline inked in 2003 and expanded last year, the company's chief executive said

Booming Clinical Research Business Could Trigger Regulatory Overhaul In India

SAN FRANCISCO - Foreign companies could soon get the go-ahead to conduct Phase I studies in India, as part of a national regulatory overhaul spurred on by booming clinical research business, regional experts say

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067697

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel